Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/IIa Study to Assess AllogeneiC Expanded Human Mesenchymal Stem Cell Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial (ACE CARD TRIAL)

Next Previous
Trial Profile

Phase I/IIa Study to Assess AllogeneiC Expanded Human Mesenchymal Stem Cell Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial (ACE CARD TRIAL)

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BCDA 03 (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Adverse reactions; First in man
  • Acronyms ACE_CARD; Allogeneic NK1R+ MSC Trial in ARDS
  • Sponsors BioCardia

Most Recent Events

  • 10 May 2023 According to a BioCardia media release, trial is expected to commence in the fourth quarter of 2023.
  • 29 Mar 2023 According to a BioCardia media release, while the number of patients with COVID-induced ARDS has decreased, ARDS, unrelated to COVID, is still significantly impacting patients. The Company intends to work with the FDA to modify the study eligibility criteria to include these patients.
  • 29 Mar 2023 According to a BioCardia media release, Clinical-grade cells have been manufactured and are available for use in this study. This trial is expected to commence following the initiation of the trial studying these allogeneic MSC cells for HFrEF.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top